Table 2.

Mortality from outcomes of interest in the full cohort and by department (1950 to 2016, US referent rates^*)

Underlying cause (ICD-10 codes)	All			San Francisco			Chicago			Philadelphia			Heterogeneity
	Obs	SMR	95% CI	Obs	SMR	95% CI	Obs	SMR	95% CI	Obs	SMR	95% CI	P value
All causes	14 057	0.97	0.95 to 0.98	2391	0.80	0.77 to 0.83	6972	1.02	1.00 to 1.05	4694	0.99	0.97 to 1.02	< 0.01
All cancersC00-C97	3843	1.12	1.08 to 1.16	655	0.95	0.88 to 1.02	1960	1.20	1.15 to 1.26	1228	1.11	1.04 to 1.17	< 0.01
MN oesophagusC15	133	1.31	1.10 to 1.55	26	1.31	0.86 to 1.92	68	1.39	1.08 to 1.77	39	1.18	0.84 to 1.62	0.71
MN stomachC16	124	1.06	0.88 to 1.27	27	1.13	0.75 to 1.65	62	1.15	0.88 to 1.48	35	0.90	0.62 to 1.25	0.46
MN intestineC17-C18	370	1.27	1.14 to 1.40	59	0.99	0.75 to 1.27	189	1.37	1.19 to 1.58	122	1.28	1.07 to 1.53	0.08
MN rectumC19-C21	97	1.32	1.07 to 1.61	20	1.33	0.81 to 2.06	52	1.53	1.14 to 2.01	25	1.02	0.66 to 1.51	0.25
MN lungC33-C34	1197	1.08	1.02 to 1.15	154	0.71	0.60 to 0.83	638	1.20	1.11 to 1.30	405	1.14	1.03 to 1.26	< 0.01
MN breastC50	10	1.24	0.59 to 2.27	NR	2.11	0.58 to 5.41	NR	1.16	0.38 to 2.71	NR	0.53	0.01 to 2.94	0.37
MN prostateC61	334	1.08	0.97 to 1.20	60	0.89	0.68 to 1.15	176	1.23	1.05 to 1.42	98	0.99	0.81 to 1.21	0.06
MN other male genitalC60, C62-C63	<5	0.39	0.11 to 1.00	<5	0.52	0.01 to 2.90	0	NC	NC	<5	0.85	0.18 to 2.49	0.15
MN kidneyC64-C66	108	1.22	1.00 to 1.47	15	0.85	0.48 to 1.40	66	1.57	1.22 to 2.00	27	0.93	0.61 to 1.36	0.02
MN bladderC67-C68	104	0.98	0.80 to 1.18	23	1.01	0.64 to 1.52	48	0.98	0.72 to 1.30	33	0.96	0.66 to 1.34	0.98
MN skinC43-C44, C46.0, C46.9	78	1.05	0.83 to 1.31	18	1.21	0.72 to 1.92	35	1.00	0.70 to 1.39	25	1.02	0.66 to 1.51	0.79
MesotheliomaC45	18	1.86	1.10 to 2.94	<5	2.00	0.54 to 5.12	10	2.14	1.03 to 3.93	<5	1.33	0.36 to 3.40	0.71
MN brainC47, C70-C72	86	0.99	0.79 to 1.23	20	1.21	0.74 to 1.87	37	0.89	0.63 to 1.23	29	1.01	0.68 to 1.45	0.55
NHLC46.3, C82-C85, C88.0, C88.3, C91.4, C96	151	1.21	1.03 to 1.42	30	1.19	0.80 to 1.70	66	1.11	0.86 to 1.41	55	1.37	1.03 to 1.78	0.51
LeukemiaC91.0-C91.3, C91.5-C91.9, C92-C95	150	1.11	0.94 to 1.31	26	0.94	0.62 to 1.38	75	1.18	0.93 to 1.48	49	1.12	0.83 to 1.48	0.61
Multiple myelomaC88.7, C88.9, C90	54	0.93	0.70 to 1.21	12	1.03	0.53 to 1.79	24	0.86	0.55 to 1.27	18	0.97	0.58 to 1.54	0.85
Ischaemic heart diseaseI20-I22, I24-I25, I51.3, I51.6	3945	0.98	0.95 to 1.01	640	0.76	0.70 to 0.82	2003	1.08	1.04 to 1.13	1302	0.98	0.93 to 1.03	< 0.01
Cerebrovascular diseaseG45.0-G45.2, G45.4-G45.9, I60-I69	725	0.90	0.83 to 0.97	145	0.83	0.70 to 0.97	341	0.93	0.84 to 1.04	239	0.90	0.79 to 1.02	0.48
COPDJ40-J44	491	0.78	0.71 to 0.85	72	0.54	0.43 to 0.68	268	0.91	0.80 to 1.03	151	0.75	0.64 to 0.88	< 0.01
Cirrhosis & other chronic liver diseaseK70, K73-K74, K76.0	321	1.16	1.03 to 1.29	71	1.37	1.07 to 1.73	156	1.16	0.98 to 1.35	94	1.03	0.84 to 1.27	0.19

Findings in bold font are statistically significant with a 95% confidence interval that excludes 1.0.

*Stratified by age (5 year intervals), gender, race (white/other) and calendar period (5 year intervals).

COPD, chronic obstructive pulmonary disease; ICD, International Classification of Diseases; MN, malignancy; NC, not calculated; NHL, non-Hodgkin's lymphoma; NR, not reported to avoid disclosing numbers less than 5; Obs, observed; SMR, standardised mortality ratio.